Correlation Between Neurocrine Biosciences and Bausch

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Neurocrine Biosciences and Bausch at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Neurocrine Biosciences and Bausch into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Neurocrine Biosciences and Bausch Health Companies, you can compare the effects of market volatilities on Neurocrine Biosciences and Bausch and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Neurocrine Biosciences with a short position of Bausch. Check out your portfolio center. Please also check ongoing floating volatility patterns of Neurocrine Biosciences and Bausch.

Diversification Opportunities for Neurocrine Biosciences and Bausch

0.25
  Correlation Coefficient

Modest diversification

The 3 months correlation between Neurocrine and Bausch is 0.25. Overlapping area represents the amount of risk that can be diversified away by holding Neurocrine Biosciences and Bausch Health Companies in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Bausch Health Companies and Neurocrine Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Neurocrine Biosciences are associated (or correlated) with Bausch. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Bausch Health Companies has no effect on the direction of Neurocrine Biosciences i.e., Neurocrine Biosciences and Bausch go up and down completely randomly.

Pair Corralation between Neurocrine Biosciences and Bausch

Given the investment horizon of 90 days Neurocrine Biosciences is expected to generate 0.2 times more return on investment than Bausch. However, Neurocrine Biosciences is 4.99 times less risky than Bausch. It trades about 0.22 of its potential returns per unit of risk. Bausch Health Companies is currently generating about -0.3 per unit of risk. If you would invest  12,711  in Neurocrine Biosciences on September 24, 2024 and sell it today you would earn a total of  831.00  from holding Neurocrine Biosciences or generate 6.54% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy65.0%
ValuesDaily Returns

Neurocrine Biosciences  vs.  Bausch Health Companies

 Performance 
       Timeline  
Neurocrine Biosciences 

Risk-Adjusted Performance

11 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Neurocrine Biosciences are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady forward indicators, Neurocrine Biosciences showed solid returns over the last few months and may actually be approaching a breakup point.
Bausch Health Companies 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Bausch Health Companies has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Bond's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for Bausch Health Companies investors.

Neurocrine Biosciences and Bausch Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Neurocrine Biosciences and Bausch

The main advantage of trading using opposite Neurocrine Biosciences and Bausch positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Neurocrine Biosciences position performs unexpectedly, Bausch can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bausch will offset losses from the drop in Bausch's long position.
The idea behind Neurocrine Biosciences and Bausch Health Companies pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Other Complementary Tools

Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Share Portfolio
Track or share privately all of your investments from the convenience of any device